Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SHE:000766)
China
· Delayed Price · Currency is CNY 19.64
+0.29 (1.50%)
May 14, 2025, 2:45 PM CST
SHE:000766 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,322 | 1,470 | 1,470 | 1,514 | 1,111 | Upgrade
|
| Other Revenue | 0.5 | 3.57 | 0.58 | 1.32 | 0.72 | Upgrade
|
| Revenue | 1,323 | 1,473 | 1,471 | 1,515 | 1,112 | Upgrade
|
| Revenue Growth (YoY) | -10.23% | 0.18% | -2.95% | 36.31% | -43.77% | Upgrade
|
| Cost of Revenue | 329.03 | 381.17 | 352.93 | 350.18 | 229.94 | Upgrade
|
| Gross Profit | 993.53 | 1,092 | 1,118 | 1,165 | 881.86 | Upgrade
|
| Selling, General & Admin | 789.26 | 905 | 923.47 | 986.24 | 1,042 | Upgrade
|
| Research & Development | 50.34 | 45.82 | 64.91 | 63.52 | 50.33 | Upgrade
|
| Other Operating Expenses | 9.88 | 10.62 | 5.52 | 5.4 | 3.96 | Upgrade
|
| Operating Expenses | 853.14 | 970.43 | 990.81 | 1,052 | 1,228 | Upgrade
|
| Operating Income | 140.39 | 121.75 | 127.01 | 113.33 | -346.24 | Upgrade
|
| Interest Expense | -84.98 | -83.15 | -88.79 | -97.19 | -125.27 | Upgrade
|
| Interest & Investment Income | 5.28 | 4.02 | 11.5 | 26.36 | 23.31 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.66 | 1.23 | -3.64 | 3.47 | -0.37 | Upgrade
|
| EBT Excluding Unusual Items | 58.03 | 43.85 | 46.08 | 45.98 | -448.58 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.03 | -2.61 | -0.05 | -0.01 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.17 | -0.21 | -0.02 | 0.83 | 57.58 | Upgrade
|
| Asset Writedown | -0.12 | 0.22 | -0.11 | -1.49 | -0.43 | Upgrade
|
| Other Unusual Items | 9.32 | 13.61 | 4.28 | 14.32 | 35.6 | Upgrade
|
| Pretax Income | 67.09 | 54.86 | 50.17 | 59.62 | -355.83 | Upgrade
|
| Income Tax Expense | 11.11 | 11.63 | 20.99 | 25.64 | 4.83 | Upgrade
|
| Earnings From Continuing Operations | 55.98 | 43.23 | 29.19 | 33.99 | -360.66 | Upgrade
|
| Minority Interest in Earnings | 0.46 | 0.71 | 0.96 | 1.29 | 1.16 | Upgrade
|
| Net Income | 56.44 | 43.93 | 30.15 | 35.27 | -359.5 | Upgrade
|
| Net Income to Common | 56.44 | 43.93 | 30.15 | 35.27 | -359.5 | Upgrade
|
| Net Income Growth | 28.46% | 45.71% | -14.52% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 941 | 879 | 1,005 | 882 | 972 | Upgrade
|
| Shares Outstanding (Diluted) | 941 | 879 | 1,005 | 882 | 972 | Upgrade
|
| Shares Change (YoY) | 7.05% | -12.57% | 13.97% | -9.24% | 0.40% | Upgrade
|
| EPS (Basic) | 0.06 | 0.05 | 0.03 | 0.04 | -0.37 | Upgrade
|
| EPS (Diluted) | 0.06 | 0.05 | 0.03 | 0.04 | -0.37 | Upgrade
|
| EPS Growth | 20.00% | 66.67% | -25.00% | - | - | Upgrade
|
| Free Cash Flow | 113.58 | 86.11 | 174.42 | 112.85 | 61.55 | Upgrade
|
| Free Cash Flow Per Share | 0.12 | 0.10 | 0.17 | 0.13 | 0.06 | Upgrade
|
| Gross Margin | 75.12% | 74.13% | 76.00% | 76.89% | 79.32% | Upgrade
|
| Operating Margin | 10.62% | 8.26% | 8.64% | 7.48% | -31.14% | Upgrade
|
| Profit Margin | 4.27% | 2.98% | 2.05% | 2.33% | -32.34% | Upgrade
|
| Free Cash Flow Margin | 8.59% | 5.85% | 11.86% | 7.45% | 5.54% | Upgrade
|
| EBITDA | 204.82 | 196.49 | 198.19 | 182.72 | -278.53 | Upgrade
|
| EBITDA Margin | 15.49% | 13.34% | 13.48% | 12.06% | -25.05% | Upgrade
|
| D&A For EBITDA | 64.42 | 74.74 | 71.18 | 69.39 | 67.71 | Upgrade
|
| EBIT | 140.39 | 121.75 | 127.01 | 113.33 | -346.24 | Upgrade
|
| EBIT Margin | 10.62% | 8.26% | 8.64% | 7.48% | -31.14% | Upgrade
|
| Effective Tax Rate | 16.56% | 21.20% | 41.83% | 42.99% | - | Upgrade
|
| Revenue as Reported | 1,323 | 1,473 | 1,471 | 1,515 | 1,112 | Upgrade
|
| Advertising Expenses | 249.73 | 352.83 | 298.68 | 375.06 | 299.1 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.